ArticleJACC. Advances2026
Long-Term Outcomes of Targeted Volume Overload Management in Patients With Severe Aortic Stenosis.
Article in JACC. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Myocardial remodeling in valvular heart disease: pathophysiology, multimodality imaging and treatment implications.Heart failure reviews · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with severe aortic stenosis (AS) and volume overload (VO) remain at an increased risk for heart failure and death after transcatheter aortic valve replacement (TAVR). The EASE-TAVR (Bioimpedance guided management of patients scheduled for transcatheter aortic valve replacement) trial demonstrated that decongestive treatment by bioimpedance spectroscopy (BIS) improves 1-year outcomes post-TAVR, whereas long-term effects are unknown.
objectivesThis study aimed to investigate outcomes of BIS-guided decongestion in AS patients at 36 months after TAVR.
methodsEASE-TAVR randomized patients with severe AS and VO defined by BIS (≥1.0 L and/or ≥7%) 1:1 into: 1) BIS-guided decongestion (n = 55); or 2) decongestion by clinical judgment alone (n = 56) post-TAVR. Patients without VO (n = 121) served as the euvolemic control group. BIS-guided decongestion was performed for 12 months. The primary endpoint was a composite of heart failure hospitalization (HFH) and all-cause death at 36 months. The secondary endpoints included separate analyses of primary endpoint components and frequency of HFH.
resultsPatients in the BIS-guided group had higher diuretic doses compared to the non-BIS-guided group throughout the entire study. At 36 months, the primary endpoint occurred in 21.8% in the BIS-guided and 46.4% in the non-BIS-guided group yielding a hazard reduction of 60% (HR: 0.40; 95% CI: 0.20-0.79). BIS-guided decongestion led to a reduced cumulative incidence of first HFH (3.6%; 95% CI: 0.7-11.2 vs 25.0%; 95% CI: 14.5-37.0), a reduced HFH frequency (28 vs 173 per 1,000 patient years; P < 0.001), and showed a nonsignificant reduced mortality hazard (HR: 0.54; 95% CI: 0.26-1.14) compared to decongestion as per clinical judgment alone.
conclusionsIn patients with severe AS and VO, outcome benefits of BIS-targeted decongestive treatment persist up to 3 years after TAVR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.